Oxygen is everywhere on Earth today. But that hasn’t always been the case. Scientists think oxygen only became a lasting part ...

In 1869, Swiss scientist Friedrich Miescher isolated a mysterious substance from cell nuclei—an overlooked finding that would ...

Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi (SASY.PA), opens new tab to develop therapies for autoimmune diseases in a ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Fortnite Chapter 7 Season 1, also known as Pacific Break, is officially here, and you'll explore the Golden Coast, which is based off of the west side of the United States. As always, with a new ...

Fortnite Chapter 7 Season 1, also known as Pacific Break, will launch on Saturday, Nov. 29 with a Hollywood and U.S. theme. Expect to see iconic characters from hit movies like The Bride from Kill ...

New multi-omic data reveal that GLP-1 signaling in the brain can drive body-wide rejuvenation, offering a potential weight-neutral path to preserving strength and organ resilience with age. Study: ...

Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility of our teams in what ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A new Cambridge biotech company ...

The use of B-cell–depleting antibodies for autoimmune disease has been well validated with significant use of Roche Holdings AG (OTC:RHHBY) and Biogen Inc (NASDAQ:BIIB) partnered Rituxan (rituximab) ...

Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in ...